TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Options calculator
  • Leaderboards
  • Insider trades
  • 13F funds
  • Groups
  • Trending
  • News

More

  • Pricing
  • Feedback
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerFeedback
Home›TNYA›Financials
Annual statements · SEC XBRL · FY2020 – FY2025

Tenaya Therapeutics, Inc. (TNYA) financials

Income statement

Tenaya Therapeutics, Inc. (TNYA) income statement, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating income-$38.9M-$72.8M-$126M-$131M-$116M-$93.3M
Net income-$38.4M-$72.7M-$124M-$124M-$111M-$90.6M
EPS (diluted)-$39.50-$4.10-$2.76-$1.68-$1.31-$0.59

Cash flow

Tenaya Therapeutics, Inc. (TNYA) cash flow, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-$35.4M-$60.8M-$104M-$102M-$90.5M-$68.3M
Capital expenditures$9.76M$25.1M$20.6M$1.24M$1.02M$618K
Free cash flow-$45.2M-$85.9M-$125M-$103M-$91.5M-$68.9M
Share buybacks$1.00K$13.0K————

Balance sheet

Tenaya Therapeutics, Inc. (TNYA) balance sheet, annual, from SEC filings
Fiscal yearFY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$129M$38.1M$95.3M$45.7M$4.32M$101M
Total assets$148M$314M$279M$171M$120M$147M
Total liabilities$8.72M$35.7M$35.6M$31.1M$27.1M$23.7M
Shareholders' equity-$81.3M$279M$243M$139M$92.9M$123M
Retained earnings-$82.8M-$156M-$279M-$403M-$514M-$605M
Shares (wtd avg diluted)1.21M17.7M44.8M73.8M84.8M153M

Every figure is extracted from Tenaya Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.

Common questions

What is Tenaya Therapeutics, Inc.'s free cash flow?
-$68.9M in FY2025 (operating cash flow -$68.3M minus $618K of capital expenditures), from the SEC cash-flow statement.
Does TNYA pay a dividend?
Tenaya Therapeutics, Inc. reported no cash dividends paid in FY2025, per its SEC cash-flow statement.
Full TNYA analysis — verdict, score & filings →Is TNYA a buy? →

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.